Pricing

Global Blood Therapeutics Inc (GBT)

followers ·
Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Ted W. Love
Employees:
460
181 OYSTER POINT BLVD, SOUTH SAN FRANCISCO, CA, 94080
650741-7700
Global Blood Therapeutics, Inc. engages in the discovery, development, and delivery of treatments for sickle cell disease (SCD) The company is developing its lead product candidate inclacumab, novel human monoclonal antibody, which is in Phase III a clinical trial to reduce the incidence of painful vaso-occlusive crises, and resulting hospital admissions. The company offers Oxbryta tablets, an oral, once-daily therapy for SCD.
All 13F Filers Prior Change Hedge Funds 1 Prior Change
InvestorHistoryShares Held or Principal AmtMarket Value% of PortfolioPrevious % of PortfolioRankChange in Shares% OwnershipQtr 1st OwnedEst. Avg PriceSourceSource DateDate Reported
No data available